Merck (MRK.US) announced that the investigational respiratory syncytial virus (RSV) prophylactic monoclonal antibody clesrovimab (MK-1654) achieved positive results in phase 2b/3 clinical trials.
Merck (MRK.US) announced that the investigational respiratory syncytial virus (RSV) prophylactic monoclonal antibody clesrovimab (MK-1654) achieved positive results in phase 2b/3 clinical trials. The antibody aims to protect infants from RSV disease. In the trial, clesrovimab reached the primary safety and efficacy endpoints, including reducing the lower respiratory tract infections (MALRI) caused by RSV that require medical intervention prior to day 150. The detailed results of this study will be presented at an upcoming scientific conference, and Merck plans to submit this data to global regulatory institutions.
Clesrovimab is a monoclonal antibody with prolonged half-life developed as a passive immunization measure for preventing RSV-related MALRI. Clesrovimab is being studied in premature and full-term infants to provide rapid and persistent protection in their first RSV season by a single, fixed dose.
